NIPD Genetics

nipd.com

NIPD Genetics is an innovative biotechnology company that specializes in non-invasive diagnostics. Through Research & Development we are committed to delivering improved solutions for the diagnosis and management of genetic diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

news image

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More

Industrial Impact

MYCOWORKS SECURES STRATEGIC INVESTMENT FROM GM VENTURES TO DEVELOP FINE MYCELIUM MATERIALS FOR SUSTAINABLE AUTOMOTIVE INTERIORS

MycoWorks | October 19, 2022

news image

Biotechnology company MycoWorks announced today its newest investor GM Ventures, the investment arm of General Motors Co. and their long-term agreement to co-develop Fine Mycelium™ materials for potential use in a range of applications within automotive design. MycoWorks' collaboration with GM marks the exploration of its entry into one of the largest end-use markets for leather and demonstrates the significant opportunity to create more sustainable materials for the automotive space.<...

Read More

Medical

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

news image

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More

Cell and Gene Therapy

ZHONGCHAO INC. ANNOUNCES ITS NEW STRATEGY EXTENSION FOCUSING ON THE ONCOLOGY AND OTHER MAJOR DISEASE MANAGEMENT

Zhongchao Inc. | September 02, 2022

news image

Zhongchao Inc. an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated exp...

Read More
news image

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More
news image

Industrial Impact

MYCOWORKS SECURES STRATEGIC INVESTMENT FROM GM VENTURES TO DEVELOP FINE MYCELIUM MATERIALS FOR SUSTAINABLE AUTOMOTIVE INTERIORS

MycoWorks | October 19, 2022

Biotechnology company MycoWorks announced today its newest investor GM Ventures, the investment arm of General Motors Co. and their long-term agreement to co-develop Fine Mycelium™ materials for potential use in a range of applications within automotive design. MycoWorks' collaboration with GM marks the exploration of its entry into one of the largest end-use markets for leather and demonstrates the significant opportunity to create more sustainable materials for the automotive space.<...

Read More
news image

Medical

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More
news image

Cell and Gene Therapy

ZHONGCHAO INC. ANNOUNCES ITS NEW STRATEGY EXTENSION FOCUSING ON THE ONCOLOGY AND OTHER MAJOR DISEASE MANAGEMENT

Zhongchao Inc. | September 02, 2022

Zhongchao Inc. an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated exp...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us